This article is more than 5 years old. Information may no longer be current.
Intravitreal bevacizumab stabilizes subfoveal CNV secondary to AMD at 2 years
Ophthalmol. 2010;117:1974-1981.
Click Here to Manage Email Alerts
Intravitreal bevacizumab improved visual acuity and macular thickness in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration, a study found.
Patients received 1.25-mg and 2.5-mg doses of Avastin (bevacizumab, Genentech).
"Our results show no significant difference regarding [best corrected visual acuity] with [intravitreal bevacizumab] at doses of 1.25 or 2.5 mg," the study authors said. "We found low rates of systemic adverse events in both groups, although there were more in the higher dose group, but the difference was not significant. Unless data to support improved efficacy for the 2.5-mg dose become available, we favor the lower dose."
The retrospective, multicenter study included 207 eyes of 180 patients with subfoveal CNV secondary to AMD. Mean patient age was 74.3 years. Eyes received a mean 5.1 injections.
Study data showed that logMAR BCVA improved from 20/235 at baseline to 20/172 at 24 months among the 1.25-mg group. The improvement was statistically significant (P < .0001).
In the 2.5-mg group, logMAR BCVA improved from 20/285 at baseline to 20/205 at 24 months (P = .002).
Mean central macular thickness diminished from 308.4 µm at baseline to 249.27 µm at 24 months in the 1.25-mg group. In the 2.5-mg group, mean central macular thickness decreased from 411.17 µm at baseline to 254.19 µm at 24 months. Central macular thickness reduction was statistically significant in both dosage groups (P < .0001).